Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy Journal Article

   

Authors:	Krebs, S.; O'Donoghue, J. A.; Biegel, E.; Beattie, B. J.; Reidy, D.; Lyashchenko, S. K.; Lewis, J. S.; Bodei, L.; Weber, W. A.; Pandit-Taskar, N.
Article Title:	Comparison of (68)Ga-DOTA-JR11 PET/CT with dosimetric (177)Lu-satoreotide tetraxetan ((177)Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
Abstract:	Purpose: Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of 68Ga-DOTA-JR11 and 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) in patients with NETs. Methods: As part of a prospective clinical trial, 20 patients with metastatic NETs underwent 68Ga-DOTA-JR11 PET/CT and serial imaging with 177Lu-satoreotide tetraxetan. PET/CT and SPECT/CT parameters for lesion uptake and absorbed dose of 177Lu-satoreotide tetraxetan in lesions were compared using linear regression analysis and Pearson correlation. Results: A total of 95 lesions were analyzed on 68Ga-DOTA-JR11 PET/CT and 177Lu-satoreotide tetraxetan SPECT/CT. SUVs and tumor-to-normal-tissue ratios on PET/CT and SPECT/CT were significantly correlated (p < 0.01), but the degree of correlation was modest with Pearson correlation coefficients ranging from 0.3 to 0.7. Variation in intrapatient lesional correlation was observed. Nevertheless, in all patients, the lesion SUVpeak uptake ratio for 177Lu-satoreotide tetraxetan vs. 68Ga-DOTA-JR11 was high; even in those with low uptake on 68Ga-DOTA-JR11 PET/CT (SUVpeak ≤ 10), a ratio of 8.0 ± 5.2 was noted. Correlation of SUVpeak of 68Ga-DOTA-JR11 with projected 177Lu-satoreotide tetratexan-absorbed dose (n = 42) was modest (r = 0.5, p < 0.01), while excellent correlation of SUVpeak of 177Lu-satoreotide tetraxetan with projected 177Lu-satoreotide tetraxetan-absorbed dose was noted (r = 0.9, p < 0.0001). Conclusion: Our study shows that 68Ga-DOTA-JR11 PET can be used for patient selection and PRRT and that low tumor uptake on PET should not preclude patients from treatment with 177Lu-satoreotide tetraxetan. The ability to use single time-point SPECT/CT for absorbed dose calculations could facilitate dosimetry regimens, save costs, and improve patient convenience. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
Keywords:	dosimetry; neuroendocrine tumors; somatostatin receptor antagonists; 177lu-satoreotide tetraxetan; 68ga-dota-jr11
Journal Title:	European Journal of Nuclear Medicine and Molecular Imaging
Volume:	47
Issue:	13
ISSN:	1619-7070
Publisher:	Springer
Date Published:	2020-12-01
Start Page:	3047
End Page:	3057
Language:	English
DOI:	10.1007/s00259-020-04832-9
PUBMED:	32378020
PROVIDER:	scopus
PMCID:	PMC7644587
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085153949&doi=10.1007%2fs00259-020-04832-9&partnerID=40&md5=529a6bb99dbf6a65df995433a3d5c6bc
Notes:	Article -- Export Date: 1 December 2020 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/173314